Mercado's heavy immunotherapy Keytruda wins two new adaptations

today, MsSD announced that its heavy immunotherapy Keytruda has won two new indicationsKeytruda has been approved by the U.SFDA(http://as a single-line treatment for patients with advanced head and neck cancer that expresses PD-L1In addition, Keytruda can be combined with common chemotherapy regimens to treat patients with advanced head and neck cancer first-lineAs a revolutionary immunotherapy, Keytruda has been approved to treat a variety of different types of cancer, including recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)2016, the FDA accelerated its approval to allow HNSCC patients whose disease struck back after platinum-based chemotherapy could be treated with KeytrudaIt is important to note that the approval spree three years ago was based on objective mitigation rate dataAfter accelerating the approval, the FDA is still asking Mercadon to provide more evidence of Keytruda's clinical gainsKeytruda also highlights the significant benefits of total lifetime (OS) in the key Phase 3 ClinicalTrial(http://known as KEYNOTE-048In patients with tumor expression PD-L1, Keytruda single-drug therapy significantly extended OS compared to standard therapies (cetuximab, caplatinum or cisplatin, and fluoroureuritosineKeytruda also significantly extends OS without taking into account PD-L1 expressionBased on these positive data on lifetimes, the FDA has also approved them as a result, Keytruda became the first anti-PD-1 therapy in these patient populations to demonstrate significant improvements in survival